AB928

AB928 is a dual antagonist of the A2aR and A2bR adenosine receptors leads to greater immune activation and reduced tumor growth when combined with chemotherapy (In Vitro) :In human in vitro cell cultures, moDC differentiated in the presence of adenosine showed a decreased ability to stimulate IFN-γ secretion from allogenic CD4+ T-cells in a MLR. This suppression is significantly reversed by addition of Etrumadenant. Multiplexed gene expression profiling using NanoString identified a cassette of 39 genes that are regulated by adenosine during moDC differentiation. Etrumadenant shows rescue of these gene expression changes. (In Vivo) :Concurrent treatment with Etrumadenant and chemotherapy results in significantly reduced tumor volume in vivo using AT3-OVA tumors; Similar results are observed for the combination of Etrumadenant and NSC 266046. AB928 is also capable of suppressing growth of B16-F10 tumors both as a single agent or in combination with α-PD-1 therapy. Etrumadenant increases the antitumor immune response leading to suppressed tumor growth and increased immune cell infiltration in mouse syngeneic tumors.

2239273-34-6

AB928 | AB-928 | AB 928

>98% (HPLC)

DMSO : 250 mg/mL (586.21 mM; Need ultrasonic)

N#CC1=CC=CC (C2=NC (N) =NC (C3=CN (CC4=NC (C (C) (O) C) =CC=C4) N=N3) =C2) =C1C

C??H??N?O

426.47

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.